This article was originally published in The Tan Sheet
"The opportunity to conduct placebo-controlled statin trials may soon disappear" due to trends toward broader statin use in the U.S. and UK populations, Ernest Hawk, MD, and Jaye Viner, MD, National Cancer Institute, state in a recent editorial in the New England Journal of Medicine. "Current treatment guidelines specify the use of statin therapy in patients at high risk for cardiovascular disease, but placebo-controlled testing against a variety of end points could still be ethically conducted in populations at average risk," the authors maintain. The editorial accompanies a study by Jenny Poynter, University of Michigan, et al., linking statins including Zocor (simvastatin) and Pravachol (pravastatin) to a significantly reduced relative risk of colorectal cancer...
You may also be interested in...
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.